ArticleRMD open2023
Clinical, radiological and pathological features of anti-MDA5 antibody-associated interstitial lung disease.
Article in RMD open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Predictors of rapidly progressive interstitial lung disease in anti-MDA5 dermatomyositis: a meta-analysis.Rheumatology (Oxford, England) · 2026Pooled it
- Influencing factors for rapidly progressive interstitial lung disease in patients with anti-MDA5 antibody-positive dermatomyositis: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- MSCs/EVs-based therapy targeting DAD: research progress and future perspectives from ARDS and COVID-19 to RP-ILD.Stem cell research & therapy · 2026Review
- Management and Prognosis of Anti-MDA5 Dermatomyositis: Insights from a National Multicenter Cohort.Biomedicines · 2026Article
- Janus kinase and calcineurin-inhibitor combination in anti-MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile.Journal of internal medicine · 2026Article
- Clinical features and prognostic factors of anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease with spontaneous mediastinal emphysema: a retrospective case series of nine patients.Frontiers in medicine · 2026Article
- Longitudinal change of idiopathic inflammatory myopathy-associated interstitial lung disease on high-resolution computed tomography, a prospective cohort study.BMC pulmonary medicine · 2025Article
- High-Resolution CT Findings in Interstitial Lung Disease Associated with Connective Tissue Diseases: Differentiating Patterns for Clinical Practice-A Systematic Review with Meta-Analysis.Journal of clinical medicine · 2025Review
- Deep learning for classifying imaging patterns of interstitial lung disease associated with idiopathic inflammatory myopathies.Scientific reports · 2025Article
- Connective tissue disease-associated interstitial lung disease: a rheumatologist's perspective.Breathe (Sheffield, England) · 2025Review
- Comparison of Chest High-Resolution Computed Tomography Findings in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive and Antibody-Negative Progressive Pulmonary Fibrosis with Polymyositis/Dermatomyositis.Journal of clinical medicine · 2025Article
- Clinical features and survival analysis of 40 cases of anti-MDA5 antibody-positive dermatomyositis complicated with interstitial lung disease.Arthritis research & therapy · 2025Article
- Clinical Features and Prognosis of Double-Positive Anti-MDA5 and Anti-CCP Antibodies in Dermatomyositis: A Retrospective Study.Journal of inflammation research · 2025Article
- An update on autoantibodies in the idiopathic inflammatory myopathies.Nature reviews. Rheumatology · 2025Review
- Quantitative Imaging Markers on HRCT Predict Rapid Progression and Adverse Events of Patients with Idiopathic Inflammatory Myopathies-Related Interstitial Lung Disease.International journal of general medicine · 2025Article
- Increased serum level of IL-6 predicts poor prognosis in anti-MDA5-positive dermatomyositis with rapidly progressive interstitial lung disease.Arthritis research & therapy · 2024Article
- Advances in Juvenile Dermatomyositis: Pathophysiology, Diagnosis, Treatment and Interstitial Lung Diseases-A Narrative Review.Children (Basel, Switzerland) · 2024Review
- Rapid Progression of Acute Interstitial Pneumonia in a Patient with Low MDA-5 Antibody Titer.The American journal of case reports · 2024Article
- Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress.Nature reviews. Rheumatology · 2024Review
- A 72-year-old man with acute lung injury and anti-melanoma differentiation-associated gene 5 antibody: A case report.Respiratory medicine case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo investigate the clinical, radiographic and pathological features of interstitial lung disease (ILD) in patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (anti-MDA5+DM).
methodsWe retrospectively analysed the medical records of patients with anti-MDA5+DM who had undergone radiological examination, and lung histopathology was performed on 17 of them.
resultsThis study examined 329 patients with anti-MDA5+DM, of whom 308 (93.6%) were diagnosed with ILD and 177 (53.8%) exhibited rapidly progressive ILD (RPILD). The most common radiographic patterns were organising pneumonia (OP) (43.2%), non-specific interstitial pneumonia (NSIP) (26.4%) and NSIP+OP (18.5%). Histological analysis showed NSIP (41.2%) and NSIP+OP (47.1%) to be the predominant patterns. However, in the 17 patients who underwent lung histopathology, the coincidence rate between radiological and histopathological diagnoses was only 11.8%. Compared with patients without RPILD, those with RPILD showed a higher prevalence of NSIP+OP (26.6% vs 10.7%, p=0.001) and a lower prevalence of NSIP pattern (21.5% vs 37.4%, p=0.002) on high-resolution CT. Furthermore, patients with radiographic patterns of NSIP+OP or diffuse alveolar damage (DAD) had more risk factors for poor prognosis, with 12-month mortality rates of 45.9% and 100%, respectively.
conclusionsRPILD was commonly observed in patients with anti-MDA5+DM. OP was identified as the predominant radiographic pattern, which corresponded to a histopathological pattern of NSIP or NSIP+OP. Notably, patients exhibiting radiographic patterns of NSIP+OP or DAD were shown to have a poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.